These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 9215304)

  • 1. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S; Procopio M; Maccario M; Zini M; Oleandri SE; Tassone F; Valcavi R; Ghigo E
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.
    Grottoli S; Maccario M; Procopio M; Oleandri SE; Arvat E; Gianotti L; Deghenghi R; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Dec; 135(6):678-82. PubMed ID: 9025712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension.
    Limone P; Oleandri SE; Ajmone Catt P; Grottoli S; Frangioni C; Avogadri E; Perrin M; Valetto MR; Maccario M
    J Endocrinol Invest; 1997 Nov; 20(10):616-20. PubMed ID: 9438920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M; Tassone F; Gianotti L; Lanfranco F; Grottoli S; Arvat E; Muller EE; Ghigo E
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Razzore P; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M; Invitti C; Maccario M; Grottoli S; Cavagnini F; Camanni F; Ghigo E
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Panminerva Med; 1998 Mar; 40(1):13-7. PubMed ID: 9573747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of acipimox, an antilipolytic drug, on the growth hormone (GH) response to GH-releasing hormone alone or combined with arginine in obesity.
    Maccario M; Procopio M; Grottoli S; Oleandri SE; Boffano GM; Taliano M; Camanni F; Ghigo E
    Metabolism; 1996 Mar; 45(3):342-6. PubMed ID: 8606641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism.
    Procopio M; Maccario M; Savio P; Valetto MR; Aimaretti G; Grottoli S; Oleandri SE; Baffoni C; Tassone F; Arvat E; Camanni F; Ghigo E
    Minerva Endocrinol; 1999; 24(3-4):107-11. PubMed ID: 10953725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M; Maccario M; Grottoli S; Oleandri SE; Boffano GM; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further evidence of cholinergic impairment of the neuroendocrine control of the GH secretion in Down's syndrome.
    Beccaria L; Marziani E; Manzoni P; Arvat E; Valetto MR; Gianotti L; Ghigo E; Chiumello G
    Dement Geriatr Cogn Disord; 1998; 9(2):78-81. PubMed ID: 9524798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity.
    Maccario M; Grottoli S; Razzore P; Procopio M; Oleandri SE; Ciccarelli E; Camanni F; Ghigo E
    Eur J Endocrinol; 1996 Aug; 135(2):205-10. PubMed ID: 8810734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence against depletion of the growth hormone (GH)-releasable pool in human primary hypothyroidism: studies with GH-releasing hormone, pyridostigmine, and arginine.
    Valcavi R; Valente F; Dieguez C; Zini M; Procopio M; Portioli I; Ghigo E
    J Clin Endocrinol Metab; 1993 Sep; 77(3):616-20. PubMed ID: 8103770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of withdrawal of somatostatin plus GH-releasing hormone as a stimulus of GH secretion in obesity.
    Alvarez P; Isidro L; Leal-Cerro A; Casanueva FF; Dieguez C; Cordido F
    Clin Endocrinol (Oxf); 2002 Apr; 56(4):487-92. PubMed ID: 11966741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E; Gianotti L; Grottoli S; Imbimbo BP; Lenaerts V; Deghenghi R; Camanni F; Ghigo E
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism.
    Cordido F; Fernandez T; Martinez T; Peñalva A; Peinó R; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1998 Dec; 83(12):4350-4. PubMed ID: 9851776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
    Ghigo E; Procopio M; Maccario M; Bellone J; Arvat E; Campana S; Boghen MF; Camanni F
    Horm Metab Res; 1993 Jun; 25(6):305-8. PubMed ID: 8344645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E; Goffi S; Nicolosi M; Arvat E; Valente F; Mazza E; Ghigo MC; Camanni F
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
    Kelijman M; Frohman LA
    J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans.
    Gianotti L; Maccario M; Lanfranco F; Ramunni J; Di Vito L; Grottoli S; Muller EE; Ghigo E; Arvat E
    J Clin Endocrinol Metab; 2000 Oct; 85(10):3604-8. PubMed ID: 11061509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.